Changes in the definition of a Clinical Trial related to the Investigational Medicinal Product initiate the following variations that have to be reported to the competent Health Authorities:

• T.II.1 Introduction of a new IMP Preparation Production Chain
• T.II.2 Introduction of a new Investigational MP (form/dosage)